Dongkook Pharmaceutical Insadol Wins Grand Prize in Gum Medicine Category at the '2026 National Industry Awards'

Dongkook Pharmaceutical announced on the 23rd that its product "Insadol" received the Grand Prize in the Gum Medicine category at the "2026 National Industry Awards" ceremony held at EL Tower in Seocho-gu, Seoul, on the 16th.

The National Industry Awards, hosted by the Industrial Policy Research Institute and sponsored by the Ministry of Trade, Industry and Energy and the Ministry of SMEs and Startups, is the nation's most prestigious industrial brand awards ceremony, selecting companies, institutions, and brands that have achieved outstanding performance in each industry over the past year. Insadol was selected as the Grand Prize winner in the Gum Medicine category for the second consecutive year, following 2025, due to its continued growth in the domestic gum medicine market, product innovation, public interest campaign operations, and achievements in global certifications, among other factors.

Joonho Song, CEO of Dongkook Pharmaceutical (right), is taking a commemorative photo after receiving the Grand Prize in the gum medicine category at the '2026 National Industry Awards' ceremony held on the 16th at EL Tower in Seocho-gu, Seoul. Dongkook Pharmaceutical

Insadol is Dongkook Pharmaceutical’s flagship brand, trusted by consumers for a long time, and has continued to expand its product lineup with a variety of oral care products, including Insadol Plus, Winplex Toothpaste, Insadent Denture Cleanser, Chiarogel, and Insacure Solution. In particular, Insadol Plus, launched in 2014 following ten years of basic, non-clinical, and clinical research, is the country’s first patented combination gum medicine. It attracted attention as a new type of gum medicine that acts simultaneously on both the outer and inner gum layers by adding Magnolia Bark Extract, effective for gum inflammation, to the original Insadol ingredients.

In addition, Dongkook Pharmaceutical’s Insadol obtained over-the-counter (OTC) approval from Swissmedic, the Swiss Agency for Therapeutic Products, in 2024. This achievement is considered highly significant, as it recognizes Insadol’s efficacy against early gum inflammation and early periodontal disease by a regulatory agency in a leading pharmaceutical country.

Since 2009, Dongkook Pharmaceutical has also been running the "Gum Health Day" campaign every March 24 in partnership with the Korean Academy of Periodontology, striving to improve public awareness of oral health. Since 2016, it has carried out the "Parents Love and Appreciation Campaign" for elderly people living alone and has continued various CSR activities, including regular volunteer work with the in-house "Insadol Plus Love Volunteer Group."

A Dongkook Pharmaceutical marketing official commented, "For over 50 years, Insadol has protected gum health in the daily lives of consumers as Korea’s leading gum medicine brand. This award recognizes our long-standing efforts to build brand awareness and consumer trust," adding, "Based on this achievement, we will continue campaigns and social contribution activities to help improve the nation’s oral health."

This content was produced with the assistance of AI translation services.